PT Kedoya Adyaraya Tbk owns and (RSGK) Fair Value & Analysis
Healthcare · ID · Market cap 958B IDR
Fair value as of: Jul 20, 2026
From 24 valuation models · updated 21 days ago
Share price −15.0% over the past month.
A solid business, but screening 10% overvalued on our models.
What matters now
- Our model range runs from 612.44 IDR (bear) to 1,021 IDR (bull), base 816.58 IDR. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 52/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
59‑month range 610.00 IDR – 1,844 IDR · fair‑value band 612.44 IDR – 1,021 IDR · the 910.00 IDR price screens above the 816.58 IDR fair value. Dashed = 300-day average. As of Jul 20, 2026.
Analysis
PT Kedoya Adyaraya Tbk owns and (RSGK) currently trades at 910.00 IDR, while our model-based Fair Value estimate is 816.58 IDR, implying the stock looks roughly 10.3% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, PT Kedoya Adyaraya Tbk owns and generated revenue of 490B IDR at a net margin of 7.3%. Revenue grew 19.4% year over year. It earns a return on equity of 4.3%. The balance sheet holds a net cash position of 40.4B IDR. Fundamentals as of Jul 20, 2026
Our scenario range runs from 612.44 IDR (bear case) to 1,021 IDR (bull case); at 910.00 IDR, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 49% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -10%, RSGK screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (819.38 IDR) versus Earnings-Based (303.62 IDR). Highest evidence: Growth DCF (80).
Notify me when RSGK reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 38
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Kedoya Adyaraya Tbk owns and operates hospitals in Indonesia. It offers facilities, such as inpatient and outpatient services; and healthcare services, and building and operating hospitals. The company was founded in 1990 and is headquartered in Jakarta, Indonesia. PT Kedoya Adyaraya Tbk is a subsidiary of PT Sarana Meditama Metropolitan Tbk.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Kedoya Adyaraya Tbk owns and reported revenue of 470B IDR in FY2025 versus 435B IDR in FY2021, a compound +1.9%/yr. Reported net income was 34.5B IDR in FY2025, compounding −10.1%/yr from FY2021.
RSGK screens 10% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare PT Kedoya Adyaraya Tbk owns and with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Kedoya Adyaraya Tbk owns and (RSGK) overvalued or undervalued?
What is the fair value of RSGK?
What is the quality score of RSGK?
What is the revenue of PT Kedoya Adyaraya Tbk owns and (RSGK)?
What is the net profit margin of RSGK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Kedoya Adyaraya Tbk owns and and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.